Who owns the Wegovy drug — and why does it matter?

The myth that Wegovy is owned by multiple companies

One of the more persistent misconceptions floating around is that Wegovy's ownership is shared between several pharmaceutical firms, or that different countries have different rights holders who vary the product. Neither is true. Novo Nordisk holds global ownership of the semaglutide molecule as its originator, along with the Wegovy brand name. The company is headquartered in Bagsværd, Denmark, and is listed on the Copenhagen and New York stock exchanges, it became, for a period, the most valuable company in Europe, largely on the strength of GLP-1 demand.

What does vary by country is the regulatory licence, not ownership. In the United States, the FDA approved Wegovy for weight management. In the UK, the MHRA granted a separate marketing authorisation. These are distinct approvals, with distinct label wording, but the manufacturer remains the same: Novo Nordisk. Any suggestion that a third party "owns" Wegovy in the UK, or that a reseller can legitimately alter the product's supply chain, is incorrect. Authorised medicines reach UK patients through Novo Nordisk's licenced distributors only. You can read more about what Wegovy is and how it works if you want the full pharmacological picture.

The reason this matters practically: if a seller cannot trace the medicine back through the licenced UK supply chain, the product's authenticity cannot be verified. That is not a technicality, the MHRA has documented cases of counterfeit weight-loss pens containing insulin rather than semaglutide, with serious consequences for patients who used them.

Novo Nordisk's semaglutide, one molecule, several brand names

Semaglutide itself is the molecule. Novo Nordisk markets it under three distinct brand names in the UK, each with its own licence and formulation. Ozempic is a once-weekly injection for type 2 diabetes. Wegovy is a once-weekly injection licensed for weight management in adults. And as of 11 June 2026, the MHRA approved Wegovy tablets (the first oral GLP-1 medicine licensed in the UK for weight loss) making the UK the first country in Europe to authorise it.

The tablet formulation uses an absorption enhancer called SNAC to make semaglutide viable orally; it carries its own dosing schedule and is not interchangeable with the injection. Rybelsus is also an oral semaglutide tablet, but it is licensed only for type 2 diabetes and carries different strengths entirely. These distinctions matter because patients sometimes arrive at pharmacies expecting one formulation and asking for another. The underlying ownership (Novo Nordisk) is constant; the licence each product holds is not.

For a fuller look at semaglutide as a drug class, including how it acts on GLP-1 receptors to reduce appetite and slow gastric emptying, that page covers the mechanism in plain language. What's worth noting here is that Novo Nordisk has invested in semaglutide's development for over two decades, which is why the patent protection and brand architecture are so robust.

What UK patients actually need to know about supply and legitimacy

Here is the practical upshot of Novo Nordisk's ownership and the MHRA's licensing. In the UK, Wegovy can only be legally dispensed by a pharmacy against a valid prescription. The prescription must come from a suitably qualified prescriber who has assessed the patient. There is no legitimate route to Wegovy that bypasses those steps. The MHRA has been unequivocal on this point, and the Yellow Card scheme exists partly so that patients can report both suspected side effects and suspect sellers.

If you are wondering about this because you have seen offers online, on social media, or through unofficial channels claiming to supply Wegovy at unusually low prices or without clinical assessment, that is a red flag worth taking seriously. Novo Nordisk supplies through licensed distributors. A GPhC-registered pharmacy can verify its supply chain; a seller who cannot is not operating within that chain.

You can verify any online pharmacy on the GPhC's public register in under a minute. That check is free and takes less time than reading this paragraph. If cost is part of your thinking, our Wegovy pricing guide explains what a legitimate private prescription typically costs in the UK and what that price should include. It is honest reading and does not dress the numbers up.

If you are considering treatment and want to understand the full landscape first, the semaglutide overview is a good starting point, and our Wegovy information page covers eligibility, the licensed doses, and what the clinical evidence shows. We understand that navigating all of this feels like more research than you signed up for when you first looked up a weight-loss medicine, that's a completely reasonable frustration, and we'd rather give you the full picture than rush you to a decision.

If you'd like a prescriber at our GPhC-registered pharmacy to review whether Wegovy is clinically suitable for you, start your free consultation and a qualified Independent Prescriber will read your answers the same day.